Subscribe
shutterstock_528642268-1
31 July 2019AmericasSarah Morgan

Alkermes settles with Amneal over opioid dependence treatment

Biopharmaceutical company  Alkermes has entered into a settlement and licence agreement with generic maker  Amneal Pharmaceuticals to resolve an inter partes review (IPR).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Alkermes and Janssen enter arbitration over nanocrystal tech
21 April 2022   Irish biopharmaceutical company Alkermes has entered arbitration proceedings over two license agreements with Johnson & Johnson subsidiary Janssen Pharmaceuticals.
Big Pharma
PTAB institutes IPR of Nalox-1 opioid overdose treatment
29 August 2019   The US Patent Trial and Appeal Board has instituted an inter partes review into a patent covering an opioid overdose treatment owned by Nalox-1 Pharmaceuticals.


Editor's picks

‘We created law’: G1/24 and the creation of the ‘diamond standard’
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025

Editor's picks

Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Americas
Alkermes and Janssen enter arbitration over nanocrystal tech
21 April 2022   Irish biopharmaceutical company Alkermes has entered arbitration proceedings over two license agreements with Johnson & Johnson subsidiary Janssen Pharmaceuticals.
Big Pharma
PTAB institutes IPR of Nalox-1 opioid overdose treatment
29 August 2019   The US Patent Trial and Appeal Board has instituted an inter partes review into a patent covering an opioid overdose treatment owned by Nalox-1 Pharmaceuticals.

More on this story

Americas
Alkermes and Janssen enter arbitration over nanocrystal tech
21 April 2022   Irish biopharmaceutical company Alkermes has entered arbitration proceedings over two license agreements with Johnson & Johnson subsidiary Janssen Pharmaceuticals.
Big Pharma
PTAB institutes IPR of Nalox-1 opioid overdose treatment
29 August 2019   The US Patent Trial and Appeal Board has instituted an inter partes review into a patent covering an opioid overdose treatment owned by Nalox-1 Pharmaceuticals.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?